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Th  is series on Sjögren syndrome, like disease-oriented 
review series on systemic lupus erythematosus (SLE) 
[1,2], vasculitides, and comorbidities of rheumatic condi-
tions [3], consists of articles that review recent topics, 
bring us up to date, and provide innovative views [4-8]. 
Respected researchers of rheumatology and clinical 
immunology with a great deal of experience in this 
particular systemic disease provide these overviews and 
share their per  spec  tives. It is notable that the advent of 
innovative immune interventions in rheumatoid arthritis 
within the last decade and the recent approval of the anti-
B cell-activat  ing factor/B lymphocyte stimulator (anti-
BAFF/BLyS) inhibitor belimumab for SLE have changed 
the lives of our patients and the treatment arma  men-
tarium, but there is ongoing research for better thera-
peutic targets in Sjögren syndrome.
With this in mind, the authors of these reviews address 
central questions about the immunopathogenesis of 
Sjögren syndrome. Sipsas and colleagues [4] explore the 
potential role of retroviruses in initiating or maintaining 
disease. Vitali [5] examines the diﬀ  erences and similari-
ties of sicca symptoms and risk of developing lymphoma 
between patients with HIV or hepatitis C virus infection 
and those with Sjögren syndrome. Low and Witte [6] 
investi  gate the central role of type I interferons (IFNs) 
driving innate immunity. Youinou and Pers [7] address 
the obvious abnormalities of other cytokines such as 
BAFF/BLyS, interleukin-17, and tumor necrosis factor-
alpha (TNF-α) in the context of the local production in 
the inﬂ  amed salivary tissues.
While further insight into the pathogenesis of Sjögren 
syndrome in humans is of critical relevance to arrive at 
newer therapies, various preclinical models of either spon-
taneous or inducible Sjögren-like disease, as compre  hen-
sively reviewed by Delaleu and colleagues [8], are impor-
tant for testing candidate thera  peutics. In this context, the 
advantages and disadvantages of the diﬀ  erent mice strains 
remind us of the diﬀ  erent models of arthritis [9] and lupus 
[10]. While these aspects can be discussed at length, there 
is a possibility that even patients with Sjögren can repre  sent 
such heterogeneity. Moreover, Kallen  berg and colleagues 
[11] summarize the current data from various trials study-
ing inhibition of TNF-α, IFN-α, BAFF, and anti-CD20 and 
-CD22 therapy and put this in the context of what these 
trials have to say about the immune abnormalities in 
Sjögren syndrome. With the continuous initiatives of 
identifying patients’ proﬁ   les and responses [12], the 
information summarized in this review series could reﬂ  ect 
the current under  standing of the (immuno)pathogenesis 
of Sjögren syn  drome and the therapeutic possibilities and 
limita  tions, which all may support our continuous search 
for improved therapies for this interdisciplinary disease.
Abstract
The reviews in this series on Sjögren syndrome provide 
an up-to-date summary and perspectives on the 
pathogenesis of this interesting entity with glandular 
and frequently systemic manifestations, the value of 
preclinical models, and our current understanding 
of therapeutic approaches. The last of these includes 
what has been learned from trials blocking tumor 
necrosis factor and, more recently, anti-CD20 therapy. 
Potential therapeutic targets, such as blockade of the 
B cell-activating factor, the role of interferon-alpha, and 
targeting CD22, are discussed.
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